Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed Articles
GlaxoSmithKline gets US FDA approval for Boostrix to prevent tetanus, diphtheria and pertussis in older people
11 July 2011
GlaxoSmithKline to refocus some research and seek efficiencies, despite posting huge 4th-qtr 2009 profits rise; applause from Science Minister
5 February 2010
GlaxoSmithKline beats forecasts with 3rd quarter2009 profits leaping 34%, despite generic competition
28 October 2009
US FDA approves GSK's Boostrix
15 December 2008
GSK posts solid results for 1st-qtr 2007 with a 14% EPS rise despite US generic pressure
30 April 2007
GSK's Boostrix approved by US FDA
9 May 2005
GlaxoSmithKline files Boostrix BLA in USA
19 July 2004
Glaxo SmithKline, an R&D powerhouse and global number one
17 January 2000
Showing 1-11 of 11 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
